RE:IrinotecanHeineman remarked in the last quarterly that when PanCan gave us the 5 million for the FOLFIRINOX / Pelareorep trial that Pelareorep had been used before with some of the components that make up the FOLFIRINOX combo drug, namely Irinotecan as I read it.
The fact that the latest first line FDA approval on the 13 of February 2024 for NALIRIFOX is the same as FOLFIRINOX pretty much except with a new longer acting version of Irinotecan I find very interesting. It's not a big stretch that Pelareorep /NALIRIFOX could be yet another combo for Pelareorep in Pancreatic Cancer. Possibly they will comment on this in the next quarterly or one of the analysts will ask the question if they're on the ball.
Cheers!!!!!!!!!!!!!!!!!!!!!